The HMS174 strain, in the absence or presence of excess phosphate, can metabolize acetate efficiently.
Garner G. Moulton
Advertisement
Garner G. Moulton is a senior research associate in the process sciences department at the Infectious Disease Research Institute
Articles by Garner G. Moulton
The recombinant approach lends itself to the production of an inexpensive and effective vaccine at large scale.
Advertisement
Latest Updated Articles
The Effect of Limiting Phosphate Using the HMS174 Cell LinePublished: July 1st 2010 | Updated:
An Improved Manufacturing Process for a Recombinant Polyprotein VaccinePublished: January 2nd 2008 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
2
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
3
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
4
